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Specific and potent caspase inhibitors are in-
dispensable for the dissection of the intricate
pathways leading to apoptosis. We selected
a designed ankyrin repeat protein (DARPin)
from a combinatorial library that inhibits cas-
pase-2 in vitro with a subnanomolar inhibition
constant and, in contrast to the peptidic cas-
pase inhibitors, with very high specificity for
this particular caspase. The crystal structure
of this inhibitor (AR_F8) in complex with cas-
pase-2 reveals the molecular basis for the spec-
ificity and, together with kinetic analyses, the al-
losteric mechanism of inhibition. The structure
also shows a conformation of the active site
that can be exploited for the design of inhibitory
compounds. AR_F8 is a specific inhibitor of an
initiator caspase and has the potential to help
identify the function of caspase-2 in the com-
plex biological apoptotic signaling network.
INTRODUCTION
Apoptosis, or programmed cell death, is essential for nor-
mal development and tissue homeostasis of all multicellu-
lar organisms. While excessive apoptosis can cause dis-
orders such as neurodegenerative diseases, insufficient
apoptosis is a hallmark of cancer. Caspases (cysteine-
dependent aspartyl-specific proteases) are highly specific
cysteine proteases, initiating and executing apoptotic cell
death (Fuentes-Prior and Salvesen, 2004 and references
therein), and some caspases play an important role in in-
flammation. Eleven human caspases have been identified
with distinct functions in apoptosis and inflammation
(Fuentes-Prior and Salvesen, 2004; Siegel, 2006). While
some caspases are functionally well characterized, others
are still poorly understood. Caspase-2 is a classic exam-Structure 15, 6ple of the latter group, as its function has remained enig-
matic, mainly because there is no dramatic phenotype of
the caspase-2 null mouse (Bergeron et al., 1998). How-
ever, a pivotal role of caspase-2 in the initiation of the in-
trinsic apoptotic pathway has been described (Hanahan
and Weinberg, 2000). Caspase-2 appears to act upstream
of mitochondrial permeabilization and plays a critical role
as the most apical initiator caspase in DNA-damage-
induced apoptosis (Guo et al., 2002; Lassus et al., 2002;
Robertson et al., 2002, 2004). Moreover, caspase-2 is ac-
tivated in response to various anticancer agents (Ceruti
et al., 2003; Dirsch et al., 2004; Robertson et al., 2002)
and was reported to play an important role in breast can-
cer (Sevignani et al., 2003), in b-amyloid cytotoxicity (Troy
et al., 2000), and in leukemia (Estrov et al., 1998; Faderl
et al., 1999). A more recent report demonstrates that cas-
pase-2 is activated in a complex containing the death-
domain-containing protein PIDD, whose expression is
induced by the tumor suppressor p53, indicating that
increased PIDD may result in caspase-2 activation in
response to genotoxic stress (Tinel and Tschopp, 2004).
However, as the intracellular targets of caspase-2, as
well as its precise function in apoptosis, remain obscure,
further investigations are required for a better understand-
ing of this cell-death protease.
The functional investigation of caspases is challenging,
as the close relationship between the different family
members makes it difficult to assign a function or a pheno-
type to a specific caspase. Highly selective inhibitors that
function intracellularly would be required to knock out in-
dividual caspases at the protein level. Numerous peptidic
caspase inhibitors have been developed, but, reflecting
the conservation of the active-site region of caspases,
the vast majority of them lack sufficient specificity.
A possible strategy that can be used to circumvent this
problem relies on the use of proteins as inhibitors to
achieve higher selectivity. Currently, the intracellular use
of protein-based inhibitors requires transfection of the
encoding gene, which limits the use of such inhibitors to
discovery tools at this time; however, many strategies
for cellular protein uptake and gene therapy (Green25–636, May 2007 ª2007 Elsevier Ltd All rights reserved 625
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of such inhibitory proteins. This protein-based approach is
also complementary to the use of RNAi, as the specificity
of such inhibitory RNA is not always perfect, nor is the in-
hibitory effect always very strong (Jackson et al., 2003;
Sledz et al., 2003).
Such proteinaceous inhibitors are not limited to binding
the conserved active-site cleft, but could interact with the
target enzyme across a different surface, thus increasing
the chances for high specificity. Antibodies, which are
the most frequently used binding molecules, and also the
most common proteins investigated for enzyme inhibition,
may not represent the optimal solution to this problem, as
their stability depends on disulfide bridges, which cannot
form in the reducing environment of the cytoplasm (Biocca
et al., 1995; Ewert et al., 2004). With designed ankyrin
repeat proteins (DARPins), we have developed an alterna-
tive to antibodies. DARPins can be selected to bind any
given target protein with high affinity and high specificity
(Binz et al., 2004). They are well expressed, highly stable,
and do not contain cysteines, making them ideally suited
for applications in reducing environments (Amstutz et al.,
2005). We report here the selection, isolation, and charac-
terization of DARPin AR_F8, which is the first, to our knowl-
edge, specific caspase-2 inhibitor. In addition, the crystal
structure of the caspase-2/AR_F8 complex is presented,
which reveals the molecular interactions and, together
with kinetic analyses, the mechanism of inhibition that
explains the unprecedented selectivity for caspase-2.
RESULTS
Ribosome Display
Ribosome-display selection rounds with an N3C DARPin
library, consisting of an N-terminal capping repeat, three
randomized repeats, and a C-terminal capping repeat,
were performed on immobilized caspase-2 as described
(Hanes and Plu¨ckthun, 1997). The theoretical diversity of
the N3C library is 3.8 3 1023, and the DNA library used
in the selection contained at least 1010 individual mem-
bers, as estimated from the amount of ligated library
DNA (Binz et al., 2004). The diversity of the library was fur-
ther increased by introducing random errors through the
polymerase in subsequent PCR cycles. An enrichment of
binders was already observed after the second ribosome-
display selection round, but three selection rounds were
performed before analyzing the selected library members.
This yielded a pool of caspase-2-binding DARPins that
served as the starting point for a combined solid-phase
screen for binders and inhibitors.
Combined Solid-Phase Assay to Screen for Binding
and Inhibition
The pool of selected DARPins was screened for caspase-
2 inhibitors and binders by a combined solid-phase
screen (Figure 1A). The high expression level of DARPins
allowed for expression and subsequent analysis of se-
lected DARPins in a 96-well format. Caspase-2 was im-
mobilized via a biotinylation tag on neutravidin. The crude626 Structure 15, 625–636, May 2007 ª2007 Elsevier Ltd All rigbacterial extracts, each containing one specific DARPin,
were added to immobilized caspase-2, and, after exten-
sive washing, caspase-2 activity was analyzed (Figure 1A,
upper panel). After washing, binding of DARPins was de-
tected by an enzyme-linked immunosorbent assay
(ELISA) (Figure 1A, lower panel). Approximately 60
DARPins showed specific binding to caspase-2 in the
ELISA screen (signal/background R 2), whereas unse-
lected DARPins showed no interaction with immobilized
caspase-2 (data not shown). Among the 60 specific
caspase-2 binders identified, one, named AR_F8, sig-
nificantly inhibited caspase-2 in the solid-phase caspase
activity assay. AR_F8 was subsequently purified to homo-
geneity for further investigations.
Stoichiometry of the Caspase-2/AR_F8 Complex
The stoichiometry of the caspase-2/AR_F8 complex in so-
lution was investigated by multiangle light scattering. The
molecular mass was determined to be 97,000 ± 400 Da,
suggesting that two AR_F8 molecules bind to the cas-
pase-2 dimer, a finding that is consistent with the results
obtained by X-ray crystallography (see below).
Analysis of Binding and Inhibition
The affinity of the caspase-2/AR_F8 interaction was inves-
tigated by kinetic surface plasmon resonance (SPR) mea-
surements (see Figure S1 and the Supplemental Data
available with this article online). Association and dissoci-
ation experiments at various concentrations of AR_F8 with
immobilized caspase-2 yielded a dissociation constant of
KD = 4.1 nM, indicating high-affinity binding.
The diagnosis of the kinetic mechanism of AR_F8-
mediated inhibition of caspase-2 was performed with the
specific velocity plot (Figure S2), Equation 1 (Experimental
Procedures), followed by refinement with Equation 2
(Experimental Procedures) for tight-binding, hyperbolic
inhibition applied to the data shown in Figure 1B. The
overall kinetic mechanism can be classified as tight-bind-
ing, hyperbolic mixed-type, with a more competitive than
uncompetitive character. Referring to Scheme 1 (Ex-
perimental Procedures), the kinetic parameters at 25C
and pH = 6.50 were: a = 2.9 ± 0.8, b = 0.04 ± 0.01, Ki =
0.29 ± 0.02 nM, where a is the ratio of the competitive to
the uncompetitive inhibitor constant, and b is the fraction
of the turnover rate of the inhibited enzyme relative to the
uninhibited one. Thus, the inhibitor constant of the com-
petitive branch in Scheme 1 was 0.29 nM, and that of
the uncompetitive component was 0.29 nM multiplied by
a, i.e., 0.84 nM. When performing nonlinear regression
with Equation 2, it was necessary to fit the active enzyme
concentration, because the procedure requires an exact
knowledge of the active-site concentration; however,
only approximate values can be determined experimen-
tally, since no suitable caspase-2 active-site titrant is
available to date. The best-fit value of the total enzyme
concentration was 2.3 ± 0.1 nM (active site), while the con-
centration estimated from protein content was 1 nM (di-
mer concentration). This analysis agrees with structuralhts reserved
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Caspase-2: Inhibition by DesignFigure 1. Combined Solid-Phase Screen for Binders and Inhibitors
(A) The upper panel represents the caspase activity assay. The assay is carried out with the fluorescent substrate Ac-VDVAD-AMC (20 mM) in complex
with caspase-2 (20 nM), immobilized via a biotinylation tag on neutravidin, in the presence of 30 different candidate DARPins. The dashed line indi-
cates the mean enzymatic activity of the 30 assays. As shown in the lower panel, an ELISA was then used for detection of binding. The ratios of the
binding signal of the candidate protein on caspase-2 and on control wells, which were coated with protein D from phase l, are given. Values above 1
(dashed line) indicate better binding on caspase-2 than on the control surface. The signal obtained for AR_F8 is indicated with an arrow. The sche-
matic setup of each assay is also depicted; caspase-2 is shown in blue, the DARPin is shown in red, and the primary and secondary antibodies are
shown in light and dark gray, respectively. p-nitrophenylphosphate (black) was used as the substrate for the ELISA. The two assays were performed
sequentially in the same 96-well plate. The DARPins were assayed in the form of crude E. coli extracts from 1.2 ml 96-well cultures.
(B) Inhibition of caspase-2 (1 nM) by AR_F8 (1–40 nM). The solid line shows the nonlinear least-squares fit on the enzyme activity (relative fluorescence
units per second) for tight-binding conditions (Szedlacsek et al., 1988); residuals are given below.
(C) AR_F8 inhibits caspase-2 specifically. The specificity of the DARPin was examined by measuring AR_F8-mediated inhibition of caspase-2, -3, -7, -8,
and -9. The results are compared with inhibition data of the two commerciallyavailable caspase-2 inhibitors, Ac-VDVAD-CHO and Ac-LDESD-CHO. The
first column (light gray) stands for the enzymatic activity of the uninhibited caspase (= 100%), the second column (dark gray) stands for 60 nM inhibitor,
and the third column (black) stands for 150 nM inhibitor. All caspases, with the exception of caspase-9, which was assayed at 150 nM, were adjusted to
a concentration of 30 nM, while caspase-9 was assayed at 150 nM; for caspase-9 inhibitionwas tested at 300 nM and 750 nM. The substrate Ac-VDVAD-
AMC was used at 20 mM. Error bars refer to standard deviation of three individual measurements.data, revealing two independent active sites on the en-
zyme.
The apparent discrepancy between the dissociation
constant obtained by SPR analysis (KD = 4.1 nM)
and the inhibitor constants determined kinetically (Ki =
0.29 nM, aKi = 0.84 nM) can be sought in the different ex-
perimental approaches. A biotinylated, Avi-tagged variantStructure 15of the caspase was used to immobilize the enzyme for
SPR measurements. It is likely that in this system AR_F8
has binding properties slightly different from those kineti-
cally measured in solution in the presence of a substrate.
Moreover, the uncompetitive branch of the inhibition
mechanism, involving the formation of a ternary ESI com-
plex, cannot be seen in the SPR experiment., 625–636, May 2007 ª2007 Elsevier Ltd All rights reserved 627
Structure
Caspase-2: Inhibition by DesignFigure 2. Stereo Representation of the Structure of the Caspase-2/AR_F8 Complex
Caspase-2 is shown in dark blue (a subunit) and light blue (b subunit), and AR_F8 is shown in salmon. AR_F8 is bound to the back side of the active-
site-forming loop 381 (see Figure 5C) of each caspase-2 monomer. Termini and loops affected by binding of AR_F8 are shown in red. The active-site
cysteine (Cys285) and the intersubunit disulfide bond are shown in yellow.In summary, tight-binding, mixed-type inhibition of the
hyperbolic type with a subnanomolar Ki value was deter-
mined for caspase-2 inhibition by AR_F8. Mixed-type
inhibition with a significant uncompetitive contribution
indicates that AR_F8 binds the enzyme-substrate com-
plex and the free enzyme with comparable affinity, and
that AR_F8 does not substantially compete for binding
to the active site of caspase-2. Hence, the kinetic data
are consistent with our structural model, in which the
AR_F8 inhibitor does not bind in the active site, but inter-
acts elsewhere with the dimeric caspase-2 and thus func-
tions as an allosteric effector.
Specificity of AR_F8
To investigate the specificity of AR_F8, inhibition of cas-
pase-2 by AR_F8 was compared to the effect of AR_F8
on caspases-3, -7, -8, and -9, which represent the closest
homologs of caspase-2 in terms of sequence identity and
substrate specificity. AR_F8 was compared with commer-
cially available caspase-2 inhibitors, the penta-peptide
aldehydes Ac-VDVAD-CHO and Ac-LDESD-CHO. Our re-
sults demonstrate that AR_F8 exclusively inhibits cas-
pase-2, but none of the other caspases tested (Figure 1C).
Caspase-1, a representative of the cytokine activators,
was not inhibited by AR_F8 either (data not shown). The
peptidic aldehyde caspase-2 inhibitors, in contrast, sup-
pressed the enzymatic activity of all tested members of
the caspase family, albeit to varying extents (Figure 1C).
Consistent with literature data (Talanian et al., 1997),
Ac-VDVAD-CHO, commonly employed as a caspase-628 Structure 15, 625–636, May 2007 ª2007 Elsevier Ltd All rig2-specific compound, inhibits caspase-3 better than
caspase-2, and all other caspases tested show clearly
reduced enzymatic activities in the presence of this com-
pound. Ac-LDESD-CHO, used as a caspase-2 and -3
inhibitor, revealed an even more pronounced preference
for caspase-3, but it also inhibits all other representatives
of the caspase family. To test whether AR_F8 leads to un-
specific inhibition when applied at higher concentrations,
the experiment was repeated for caspases-3, -7, and -8 at
concentrations of AR_F8 of 300 nM (10-fold molar
excess), 600 nM (20-fold excess), and 1.2 mM (40-fold ex-
cess), respectively. Even at these high concentrations no
trace of inhibition was detected, underscoring the speci-
ficity of the selected inhibitor (data not shown). Due to
the low enzymatic activity, caspase-9 had to be assayed
separately (150–600 nM) and was not inhibited by the ad-
dition of greater amounts of AR_F8 (tested up to 3 mM;
data not shown).
Structure of the Caspase-2/AR_F8 Complex
The caspase-2/AR_F8 complex crystallized in space
group P21, with three complexes with a molecular mass
of 98,081 Da in the asymmetric unit. The three indepen-
dent complexes show similar conformations, and, in
each complex, two AR_F8 molecules bind to a caspase-
2 dimer (Figure 2). The coordinates of the molecule with
chains A, B, C, D, P, and Q were used in all figures. The
concave surface of AR_F8, harboring most of the random-
ized amino acids, binds to loop 381 of the caspase-2
b subunit (the numbering refers to the insertion point inhts reserved
Structure
Caspase-2: Inhibition by DesignFigure 3. Molecular Interactions between AR_F8 and Caspase-2
Stereo representation of the caspase-2/AR_F8 interface rotated 90 from the standard orientation, viewed from the back plane of the caspase, dis-
playing hydrogen bonds (green, dotted lines) and hydrophobic interactions. Interacting residues of AR_F8 are shown in red; those of caspase-2 are
shown in blue.caspase-1, see Figure 5C), which forms one rim of the
active-site cleft of the enzyme. Additional interactions
are observed with the N-terminal segment of the symmetry-
related b subunit of caspase-2 (Figure 2). When superim-
posing the structures of the caspase-2/AR_F8 complex
and of Ac-LDESD-CHO bound to caspase-2 (Schweizer
et al., 2003), differences are observed in all segments
forming the active site (Figure 2 and discussed below).
The interaction surface of the caspase-2/AR_F8 com-
plex was analyzed by using the protein-protein interaction
server (http://www.biochem.ucl.ac.uk/bsm/PP/server) and
the Protein Interfaces, Surfaces, and Assemblies (PISA)
server (http://www.ebi.ac.uk/msd-srv/prot_int/pistart.html).
The buried accessible surface area (ASA) on AR_F8 is,
on average, 852 A˚2, with a planarity index of 2.5 and a sur-
face complementarity of 0.60, involving 24 residues of
caspase-2 and 25 residues of AR_F8, respectively. The
global protein-protein interaction parameters obtained
are comparable to other known ankyrin repeat protein-
target protein complexes, to antibody-antigen interfaces,
and to other heterodimeric protein-protein interfaces (Binz
et al., 2004; Amstutz et al., 2005; Lo Conte et al., 1999).
Comparison with the Caspase-2/LDESD-CHO
Structure
To describe the interactions in detail, we use the number-
ing of the enzyme presented in the PDB file; standard
numbering of caspase-1 (Fuentes-Prior and Salvesen,
2004) is given in parentheses. Due to a hydrophobic inter-
action primarily involving Phe114 of AR_F8 and Pro275
(381c) as well as Gly276 (381d) of caspase-2, loop 381Structure 15, 6is shifted by 1 A˚ toward AR_F8, resulting in an opening
of the active-site cleft compared to other caspase-2/
peptide inhibitor structures (Figures 3, 4, 5A, and 5B). In
complex with AR_F8, Met209 (319) of the N-terminal
part of the adjacent symmetry-related b subunit of cas-
pase-2 is involved in a hydrophobic contact with Thr57
of AR_F8 and is observed 3 A˚ away from its position in
the caspase-2/LDESD complex (Schweizer et al., 2003).
In this conformation, the C-terminal part of the a subunit
is shifted, resulting in a displacement of the active-site
Cys155 (285) by 1 A˚ compared to its position when bound
to peptidic inhibitors (Figure 4). In addition, the conforma-
tion of the b strand at the bottom of the active-site cleft,
which is involved in the precise positioning of peptidic in-
hibitors, and presumably substrates, through a network of
hydrogen bonds, is different in the caspase-2/AR_F8
complex, affecting the structural organization of the S1-,
S2-, and S3-binding pockets (Figures 4, 5A, and 5B).
The global positioning of residues involved in ligand bind-
ing is only moderately affected. The disruption of the hy-
drogen-bonding network and the shift of the active-site
cysteine, however, prevent correct binding, and thus
cleavage of substrates. Furthermore, the side chain of
Tyr79 of AR_F8 interacts with caspase-2 close to its S5
pocket, and the side chain of Glu112 of AR_F8 forms a hy-
drogen bond with Lys234 (344) of caspase-2, affecting the
S4 subpocket. Thus, binding of AR_F8 also stabilizes a dif-
ferent caspase-2 conformation for the S4 and the S5 sub-
strate-binding pockets with altered shape and physical
properties (Figure 4). This renders the extended active
site inaccessible to substrates (Figures 5A and 5B).25–636, May 2007 ª2007 Elsevier Ltd All rights reserved 629
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Caspase-2: Inhibition by DesignFigure 4. Superposition of the Active Sites of the Caspase-2/Ac-LDESD-CHO and the Caspase-2/AR_F8 Structures
AR_F8 is shown in salmon, caspase-2 is shown in dark blue (large a subunit) and light blue (small b subunit), and the active-site cysteine is shown in
yellow. In the bound form, loop 381 is shifted toward the AR_F8 inhibitor. The N-terminal part of the symmetry-related b subunit (Nb0) is in a different
position from that observed in the caspase-2/LDESD-CHO complex (caspase loops, magenta; the peptide aldehyde is colored by atom type), result-
ing in a rearrangement of the C-terminal part of the a subunit (Ca) with the active-site cysteine. Also, the location of the b strand that forms the bottom
of the active site as well as the adjacent loop 341 is altered.It is a well-known fact that the active-site regions of cas-
pases are flexible and show a high degree of adaptability
when interacting with different inhibitors. In contrast to ac-
tive-site-directed inhibitors, however, AR_F8 inhibits the
enzyme by stabilizing an inactive, but probably preexist-
ing, conformation, a finding that is consistent with the
structural investigation of other DARPin inhibitor com-
plexes (Kohl et al., 2005; Sennhauser et al., 2007).
DISCUSSION
Most of the numerous substrate-derived caspase inhibi-
tors exhibit very low specificity for a particular caspase.
Such inhibitors may be useful if the activity of the entire
family, comprised of initiators and effectors of apoptosis
as well as cytokine activators, is to be suppressed
(Garcia-Calvo et al., 1998; Talanian et al., 1997). However,
with the possible exception of Ac-VYAD-CHO, a reason-
ably specific caspase-1 inhibitor, peptidic caspase inhib-
itors cannot discriminate sufficiently between individual
caspases (Garcia-Calvo et al., 1998). Some nonpeptidic
isatin caspase inhibitors have been reported to selectively
inhibit caspase-3 and caspase-7, and the anilino-quinazo-
lines inhibit caspase-3 and, to some extent, caspase-6
(Scott et al., 2003); however, despite these advances,
highly selective inhibitors of caspases are still very difficult
to design.
A fundamental disadvantage of conventional caspase
inhibitors is that they all target the conserved active-site
region, resulting in poor specificity of these compounds.
As protein surfaces display higher variability, specificity
can be increased if binding of the inhibitor is instead
targeted to the surface of caspases. Protein binders are
known to interact with their targets, forming a large inter-
action area; hence, they appear to be optimal for achiev-
ing high selectivity. Antibodies are often used for this pur-
pose, and some enzyme-inhibiting antibodies have also
been described. The use of recombinant antibodies as in-
tracellular inhibitors is limited since they contain intrado-630 Structure 15, 625–636, May 2007 ª2007 Elsevier Ltd All rigmain disulfide bridges that contribute significantly to sta-
bility (Biocca et al., 1995; Ewert et al., 2004). DARPins
bind their targets in an antibody-like manner (Binz et al.,
2004), but they contain no cysteines. Here, we show that
DARPins can act as highly specific, highly potent caspase
inhibitors that are functional under reducing conditions,
such as those found in the cell.
The high specificity of AR_F8 can be explained by the
fact that AR_F8 binds to two flexible surface regions of
caspase-2, primarily loop 381 and the N-terminal segment
of the b subunit. This selects a conformation with differ-
ences in regions directly interacting with AR_F8 (N-termi-
nal peptide of the b subunit, loop 341, loop 381) and in the
b strand adjacent to loop 341 that forms the bottom of the
active-site cavity. The caspase surfaces involved in bind-
ing display highly diverse sequence segments among all
human caspases (Figure 5C). These sequence segments,
with the exception of Asp269 (379), which is replaced by
Glu in the mouse enzyme, are identical in human and mu-
rine caspase-2. Therefore, we assume that AR_F8 also
interacts with the murine enzyme, albeit with decreased
affinity.
These findings are in line with those from a previous
study on the selection of a DARPin-based inhibitor of
a prokaryotic kinase that was shown to be fully active
in vitro and in vivo, indicating the potential of DARPins
as intracellular inhibitors (Amstutz et al., 2005). The intrin-
sic stability of the DARPin consensus structure results in
a high percentage of functional library members, minimiz-
ing the occurrence of unfolded proteins within the library.
This reduces unspecific interactions that might otherwise
be caused by ‘‘sticky’’ hydrophobic patches. Since
DARPins are well expressed as soluble proteins, we could
employ a combined solid-phase screen for binders and in-
hibitors in a 96-well format, which allows for testing of
crude bacterial extracts. This procedure may be easily
automated and is by no means limited to caspases; it
may be adapted to any other enzyme with an appropriate
activity assay. Binding of DARPins is not restricted to thehts reserved
Structure
Caspase-2: Inhibition by DesignFigure 5. Comparison of Caspase-2
Structures and Sequence Alignment of
the b Subunits of Homologous Caspases
(A) Structure and cartoon representation of the
caspase-2/LDESD-CHO complex.
(B) Structure and cartoon representation of the
caspase-2/AR_F8 complex; the AR_F8 protein
binds to loop 381 and the N-terminal part of the
symmetry-related b subunit of caspase-2.
(C) Sequence alignment of selected human
caspases. The alignment is based on the struc-
tures of the individual caspases; the numbering
refers to caspase-1. The regions located at the
interface of the caspase-2/AR_F8 complex are
boxed. Highly conserved residues are shaded
in black, and moderately conserved ones are
shaded in gray.active-site cleft, but may include many other epitopes on
the surface of the target protein. Some of these epitopes
may represent allosteric sites.
An allosteric site in caspase-7 that is located in the cen-
tral cavity at the dimer interface was reported (Hardy et al.,
2004). Here, covalent binding of small-molecule inhibitors
at the dimer interface trapped the caspase in an inactive
conformation that closely resembles its zymogen form.
As shown above, AR_F8 binds primarily to loop 381.Structure 15This loop forms one side of the active-site cleft. The inter-
action of Pro275 (381c) and Gly276 (381d) with Phe114
and Tyr122, respectively, of AR_F8 stabilizes a distinct
conformation in loop 381; there are structural differences
in the S5 and the S4 pockets compared to caspase-2
with a bound substrate analog. The structural restriction
of the S5 and S4 pockets by the side chains of Tyr79
and Gln112, respectively, of AR_F8 is most probably re-
sponsible for the competitive contribution of inhibition., 625–636, May 2007 ª2007 Elsevier Ltd All rights reserved 631
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the caspase-2/substrate analog structure occurs at the
N terminus of the proximal b subunit: the N-terminal loop
has a different conformation in the AR_F8-binding struc-
ture, and Met209 (319) of caspase-2 interacts with Thr57
of AR_F8 by a hydrophobic contact. This conformation re-
locates the C-terminal part of the a subunit and displaces
the active-site cysteine (Cys285) by 1 A˚, misaligning it
from its optimal position for nucleophilic attack. Moreover,
structural differences are found in loop 341 and the adja-
cent b strand that forms the bottom of the active-site
pocket. In this way, the hydrogen-bond interactions be-
tween enzyme and substrate are critically disturbed,
which also prevents the proper positioning of substrates
and therefore binding of substrate in a mixed-type, inhib-
itory way.
Allosteric regulation of proteins is highly effective and is
known to be a primary means of biological control. Natural
and man-made allosteric modulators offer several signifi-
cant advantages over orthosteric ligands, including
greater selectivity and saturability of their effects (Christo-
poulos, 2002). Allosteric inhibition of DARPins has been
reported for both natural ankyrins and DARPins: several
crystal structures of the cyclin-dependent kinase 6
(Cdk6) with different natural ankyrin inhibitors of the
INK4 family (p16, p18, and p19) illustrate an allosteric inhi-
bition mechanism (Brotherton et al., 1998; Jeffrey et al.,
2000; Russo et al., 1998). Recently, the crystal structure
of a DARPin, binding and inhibiting aminoglycoside phos-
photransferase (30)-IIIa, a bacterial antibiotic-resistance
enzyme, revealed an allosteric inhibition mode as well:
the inhibitor bound and stabilized a conformation of the ki-
nase, which can no longer interact with the substrate in
a productive fashion (Amstutz et al., 2005; Kohl et al.,
2005). While the development of allosteric regulators is
difficult and was to date a pure trial-and-error process re-
lying on high-throughput screening (Noble et al., 2004), we
believe that our results, together with the previous findings
regarding selection of a DARPin kinase inhibitor (Amstutz
et al., 2005; Kohl et al., 2005), indicate that (1) DARPins
themselves represent an attractive alternative to synthetic
inhibitors because they are highly specific due to the fact
that they can bind to less-conserved surface regions of
a target protein, and that (2) DARPin-target protein com-
plex structures represent an excellent starting point for
the generation of novel synthetic inhibitors based on the
nonproductive conformation of the enzyme in the com-
plex. Specific caspase inhibitors are indispensable for
the validation of pathways, for the discovery of unknown
interactions, and for the identification of novel intracellular
targets. In contrast to peptide-based caspase-2 inhibitors
that inhibit, for instance, the complete VDVADase activity
of cell lysates, AR-F8 is able to exclusively inhibit the con-
tribution arising from caspase-2.
While such protein-based inhibitors will currently serve
mostly as a discovery tool, future developments in protein
uptake and gene therapy may offer broader perspectives
for the use of such inhibitory proteins. More immediately,
the mechanistic, and especially structural, dissection of632 Structure 15, 625–636, May 2007 ª2007 Elsevier Ltd All rightheir action, as described in this work, may lead to a
new approach to small-molecule, cell-permeable inhibi-
tors: by effecting a similar allosteric transition as the inhib-
itory protein, the problem of individually addressing a
member of an enzyme family may be solved, even
when the active-site structures of the proteins are almost
identical.
EXPERIMENTAL PROCEDURES
Protein Expression and Purification
Two separate expression vectors, derived from pET11d (Novagen),
were constructed for the expression of the large p19 (MetAlaAsn150–
Asp316) and the small p12 (MetAla331–Thr435) subunits of human cas-
pase-2 (SwissProt database accession number P42575). An Avi tag
sequence (Schatz, 1993) was introduced at the N terminus of p19 to
obtain a biotinylated variant of the protein, starting with the sequence
MAGLNDIFEAQKIEWHEG. Both the caspase-2 p19 subunit, which
was expressed as inclusion bodies, and protein D from phage l
(used as a control) (Yang et al., 2000), expressed as soluble protein,
were biotinylated in vivo by using plasmid pBirAcm in E. coli BL21
(DE3) (Novagen) and E. coli XL-1 Blue (Stratagene), respectively, by
following the protocols from Avidity (Denver, CO) and QIAGEN (Hilden,
Germany). Efficient biotinylation was confirmed by ELISA, western blot
with a streptavidin-alkaline phosphatase conjugate (Roche, Switzer-
land), and mass spectrometry. The p19 and p12 subunits of both the
biotinylated and the untagged variant were expressed as inclusion
bodies, and the protease was refolded and purified as described
(Schweizer et al., 2003).
DARPins for in vitro inhibition assays were produced in soluble form
and purified by using affinity chromatography as described (Kohl et al.,
2003). For the production of caspase-3, the genes of the large p17
(MetSer29–Asp175) and the small p12 (MetAlaSer175–His277) subunits
were inserted in the NcoI-BamHI sites of the pET11d plasmids (Nova-
gen). For caspase-8, the genes encoding the large p18 (MetGlyGlu218–
Asp374) and the small p12 (MetAlaGlu376–Asp479) subunits were
inserted into the NcoI site of pET11d (Novagen). Expression, refolding,
and purification of caspase-3 and caspase-8 were performed as
described (Garcia-Calvo et al., 1998, 1999; Thornberry et al., 1997).
Caspase-7 and caspase-9 were purchased from Alexis Biochemicals
(Lausen, Switzerland).
Ribosome Display with an N3C DARPin Library
The generation of DARPin libraries has been described elsewhere
(Binz et al., 2003). Here, an N3C library was used for the selections,
encoding DARPins consisting of an N-terminal capping repeat, three
internal AR modules containing randomized residues, and a C-terminal
capping repeat. The PCR-amplified libraries of the ribosome-display
format were transcribed, and three standard ribosome-display selec-
tion rounds were performed against immobilized caspase-2 as de-
scribed (Binz et al., 2004; Hanes and Plu¨ckthun, 1997). The RT-PCR
product of the genes obtained after the third selection cycle was
then used for a single clone analysis.
Combined Solid-Phase Screening for Binders and Inhibitors
The open reading frame of the RT-PCR product encoding the selected
DARPins was ligated into pQE30 (QiAgen) via BamHI/HindIII. Single
colonies of transformed E. coli XL-1 Blue cells (Stratagene) were
used for the expression of individual AR proteins. Cells were grown
in 1.2 ml Luria Bertani/1% glucose (w/v) medium in 96-well format
deep-well plates (Abgene, UK), and proteins were expressed for 3 hr
at 37C after induction with 0.5 mM isopropyl-1-thio-b-D-galacto-
pyranoside. Cell pellets were lysed with 50 ml B-Per II (Pierce) for
10 min at room temperature with shaking, and then the lysates were
mixed with 250 ml 50 mM Tris HCl (pH 7.5), 500 mM NaCl. A centrifu-
gation step (5000 rpm, 10 min, 4C) was applied to pellet cell debris,ts reserved
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for additional experiments.
Caspase-2 was immobilized on Maxisorp 96-well plates (Nunc, Den-
mark). For the screening for caspase inhibitors, 100 ml each of the
crude E. coli extracts containing the DARPins was applied to both
wells containing immobilized caspase-2 and to wells containing the
control (protein D from phage l). To test for potential inhibitors, a cas-
pase activity assay was performed as described (Stennicke and Salve-
sen, 1999). Fluorescence of the AMC leaving group was detected at
lex = 360 nm and lem = 465 nm after a 20 min incubation at 25
C by
using an HTS 7000 Plus Bio Assay Reader (Perkin Elmer). Binding
was tested by ELISA with an anti-RGS-His antibody (QIAGEN), an
anti-mouse-IgG-alkaline phosphatase conjugate (Pierce), and p-nitro-
phenylphosphate (Fluka, Switzerland). Protein D from phage l was
used as a negative control for binding specificity for each tested
DARPin.
Crystallization and Data Collection
Crystallization
The caspase-2/AR_F8 complex was purified with Superdex 200 HR
10/30 (Amersham Pharmacia, Sweden) size-exclusion chromatogra-
phy in 50 mM Tris-HOAc (pH 7.5), 50 mM KSCN, 0.5 mM TCEP,
concentrated to 20 mg/ml by using an Amicon Ultra-4 (Millipore). Crys-
tallization trials were first performed with the Cartesian MicroSys
(Genomic Solutions Ltd., UK) at the nanoliter scale and were subse-
quently scaled up and optimized. The crystals used for data collection
were grown in 1 day at 20C in a 4 ml hanging drop containing a 1:1 ratio
of protein solution:reservoir solution (17% [w/v] PEG 5000-MME, 0.1 M
Tris-HOAc [pH 7.2], 0.1 M KSCN, and 30% [v/v] ethylene glycol).
X-Ray Diffraction Data Collection
Diffraction data were collected on a 225 CCD MarResearch detector at
the Swiss Light Source PX beamline (Villigen, Switzerland) at a wave-
length of 0.899 A˚. A single crystal was used for data collection. The
crystal diffracted to 3.2 A˚ resolution. The space group was found to
Table 1. Statistics for Data Collection and Refinement
Data Collection
Space group P21
Cell dimensions (A˚) a = 58.02, b = 229.21,
c = 114.93; a = 90,
b = 90.11, g = 90
Resolution limits (A˚) 30–3.24 (3.5–3.24)a
Observed reflections 165,291 (34,589)a
Unique reflections 92,159 (18,974)a
Completeness (%) 98.0 (98.0)a
Redundancy 1.79 (1.82)a
Rsym (% on I) 5.9 (37.9)
a
I/s 9.81 (2.41)a
Refinement
Resolution range (A˚) 20–3.24
R factor/Rfree (%) 26.2/30.5
Ordered water molecules 29
Rms deviation from ideal
Bond lengths (A˚) 0.01
Bond angles () 1.474
Average B factor (A˚2) 95.82
a Numbers in parentheses refer to the highest-resolution shell.Structure 15,be P21 (a = 58.02 A˚, b = 229.21 A˚, c = 114.93 A˚, b = 90.11
); there
were three enzyme-inhibitor complexes per asymmetric unit. The
data (see Table 1) were processed and scaled with XDS (Kabsch, 1988).
Structure Determination and Refinement
The structure was solved by molecular replacement with the program
AmoRe (Navaza, 1994), by using the caspase-2/LDESD complex
structure (1PYO [Schweizer et al., 2003]) and the DARPin structure
E3_5 (1MJ0 [Kohl et al., 2003]) as search models. Using the diffraction
data from 10 to 4 A˚, AMoRe (Navaza, 1994) indicated the presence in
the asymmetric unit of three caspase-2 dimers, each bound to two
AR_F8 molecules. The calculated solvent content was 51%. Density
modification (CCP4, 1994) (solvent flattening, histogram matching,
and 3-fold averaging) yielded phases of sufficient quality to help effec-
tive model rebuilding. The program COOT was used for this purpose
(Emsley and Cowtan, 2004). After rigid-body refinement with CNS
(Bru¨nger et al., 1998) with data from 30 to 3.24 A˚, cycles of torsion an-
gle-simulated annealing, conjugate gradient minimization refinement,
and B factor refinement were alternated with model rebuilding. NCS re-
straints were applied throughout the refinement to all protein chains. A
bulk solvent correction was also applied. A total of 29 water molecules
were introduced in the last phase of the refinement, and the unliganded
caspase-2 structure was checked for the presence of equivalent water
molecules. The final R value was 26.2%, and the Rfree was 30.5%.
Enzyme Kinetics
The concentration of the caspase substrate Ac-VDVAD-AMC was
determined spectrophotometrically after quantitative hydrolysis by
caspase-2 by using an absorption coefficient for the 7-amino-4-
methylcoumarin product of 16,000 M1 cm1 at 342 nm (Baici et al.,
1996). Initial rates of substrate hydrolysis at 25C ± 1C were mea-
sured fluorimetrically by using an HTS 7000 Plus Bio Assay Reader
(Perkin Elmer) with excitation and emission wavelengths of 360 nm
and 465 nm, respectively. The buffer was composed of 100 mM
MES (pH 6.50), 10% w/v PEG 600, 10 mM DTT, and 0.1% w/v CHAPS.
The Michaelis constant, KM = 55.3 mM, of Ac-VDVAD-AMC for cas-
pase-2 was determined by fitting the Michaelis-Menten equation to ini-
tial velocity data obtained at 15 substrate concentrations. Preliminary
measurements suggested that inhibition of caspase-2 by AR_F8 was
not of the slow-binding type, and that the interaction was relatively
tight. Thus, the inhibition mechanism was investigated in two steps.
In the first of these, the inhibition type was diagnosed by using a com-
bination of five substrate concentrations (0.25–4 times KM) and five
inhibitor concentrations in the range of 25–400 nM. Analysis of initial
velocity data for the 25 combinations of substrate and inhibitor con-
centrations were performed with the specific velocity plot, a graphical
method suitable for diagnosing linear and hyperbolic inhibition mech-
anisms (Baici, 1981). This method is based on the general modifier
mechanism shown in Scheme 1:
Scheme 1
Here, E represents the free enzyme, S represents the substrate, I
represents the AR_F8 inhibitor, and P, collectively, represents the
products of the reaction. Other symbols are as follows: Ki = [E][I]/[EI],
the competitive inhibitor constant; aKi = [ES][I]/[ESI], the uncompetitive625–636, May 2007 ª2007 Elsevier Ltd All rights reserved 633
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Caspase-2: Inhibition by Designinhibitor constant; Ks = [E][S]/[ES], the substrate dissociation constant;
aKs = [EI][S]/[ESI]; kcat, the catalytic rate constant. The dimensionless
coefficients a and b characterize the proportion of competitive and
uncompetitive character in the inhibition mechanism and the fact
that inhibition may be incomplete (hyperbolic inhibition, b < 1) at satu-
rating inhibitor, respectively. The specific velocity equation is as
follows:
n0
ni
=
½I
 1
aKi
 1
Ki

1+ b
½I
aKi
s
1+ s
+
1+
½I
Ki
1+ b
½I
aKi
; (1)
where n0 and ni are the initial velocities in the absence and in the pres-
ence of inhibitor, respectively, and s = [S]/KM; other symbols are as de-
scribed above. Plots of data derived from Equation 1 (Figure S2), col-
lected at high inhibitor concentrations to avoid inhibitor depletion and
thus allowing for the consideration of a value of [I] practically identical
to the total inhibitor added, were characteristic of hyperbolic, mixed-
type inhibition (Baici, 1981). From the specific velocity plot and its sec-
ondary plots, sufficiently precise values of a and b, and a rough esti-
mate of Ki, could be calculated. In a second approach, an accurate
value of Ki was obtained by measuring initial velocities at fixed enzyme
and substrate concentrations (1 nM and 40 mM, respectively) and sev-
eral AR_F8 concentrations (Figure 1B). The tight-binding condition and
the hyperbolic, mixed-type character of the inhibition were taken into
account with the following equation (Szedlacsek et al., 1988):
ni =
n0
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a+ s bð1+ sÞ
a+ s

8>><
>>:
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1+ s
a+ s
aKi
½Et
+
½It
½Et
 1
2
+ 4
1+ s
a+ s
aKi
½Et
s
+
a+ s+ bð1+ sÞ
a+ s bð1+ sÞ 
1+ s
a+ s
aKi
½Et
 ½It½Et
9>>=
>>;:
(2)
In Equation 2, [I]t is the total inhibitor concentration, and other sym-
bols are the same as described above. Nonlinear regression analysis
by using Equation 2 does not allow the simultaneous determination
of all parameters from a single titration curve. Therefore, we used the
a and b values determined independently with the specific velocity
plot, as well as the s = [S]/KM ratio, as constants, while retaining Ki
and the total enzyme concentration [E]t as parameters to be fitted.
Nonlinear regression analysis was performed by using GraphPad
Prism version 4.00 for Windows, GraphPad Software, San Diego, CA
(www.graphpad.com).
Caspase Activity Assays
Different inhibitors plus AR_F8 were tested in a specificity inhibition
test of caspase-2, -3, -7, -8, and -9. The concentrations of all low-
molecular mass inhibitor solutions were determined by using an amino
acid analyzer (AminoQuant, Hewlett Packard). The caspase-2, -3, -7,
and -8 concentrations in the assay were 30 nM, and the peptidic inhib-
itors or AR_F8 inhibitor was added prior to the measurement at 60 or
150 nM (corresponding to a 2-fold or 5-fold molar excess over en-
zyme). Caspase-9 was assayed at 150 nM, as its low specific activity
did not allow for accurate measurements at 30 nM, and the inhibitors
were added at 300 and 750 nM. The following substrates were used
(all at 20 mM concentration): Ac-VDVAD-AMC (Calbiochem) for cas-
pase-2 and caspase-3, Ac-DEVD-AMC (Calbiochem) for caspase-7
and caspase-8, and Ac-LEHD-AMC (Alexis Biochemicals) for cas-
pase-9. The initial velocities were determined by following the protocol
for the standard caspase activity assay (Stennicke and Salvesen,
1999).
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